Key result
Myosin isolated from hypertrophic cardiomyopathy myectomy samples showed a 21% reduction in the fraction of actin filaments moving compared with donor myosin.
Observational
Answers are grounded in this paper and cite their sources.
Supports intrinsic myosin dysfunction in HCM; hypothesis-generating for sarcomere-targeted therapies pending further validation.
AIM: The aim of the study was to compare the functional and structural properties of the motor protein, myosin, and isolated myocyte contractility in heart muscle excised from hypertrophic cardiomyopathy patients by surgical myectomy with explanted failing heart and non-failing donor heart muscle. METHODS: Myosin was isolated and studied using an in vitro motility assay. The distribution of myosin light chain-1 isoforms was measured by two-dimensional electrophoresis. Myosin light chain-2 phosphorylation was measured by sodium dodecyl sulphate-polyacrylamide gel electrophoresis using Pro-Q Diamond phosphoprotein stain. RESULTS: The fraction of actin filaments moving when powered by myectomy myosin was 21% less than with donor myosin (P = 0.006), whereas the sliding speed was not different (0.310 +/- 0.034 for myectomy myosin vs. 0.305 +/- 0.019 microm/s for donor myosin in six paired experiments). Failing heart myosin showed 18% reduced motility. One myectomy myosin sample produced a consistently higher sliding speed than donor heart myosin and was identified with a disease-causing heavy chain mutation (V606M). In myectomy myosin, the level of atrial light chain-1 relative to ventricular light chain-1 was 20 +/- 5% compared with 11 +/- 5% in donor heart myosin and the level of myosin light chain-2 phosphorylation was decreased by 30-45%. Isolated cardiomyocytes showed reduced contraction amplitude (1.61 +/- 0.25 vs. 3.58 +/- 0.40%) and reduced relaxation rates compared with donor myocytes (TT(50%) = 0.32 +/- 0.09 vs. 0.17 +/- 0.02 s). CONCLUSION: Contractility in myectomy samples resembles the hypocontractile phenotype found in end-stage failing heart muscle irrespective of the primary stimulus, and this phenotype is not a direct effect of the hypertrophy-inducing mutation. The presence of a myosin heavy chain mutation causing hypertrophic cardiomyopathy can be predicted from a simple functional assay.
No takes yet. Share an insight, caveat, or question.
Jacques et al. (2008) conducted an observational in Hypertrophic obstructive cardiomyopathy. Myectomy myosin (HCM) vs. Donor myosin and failing heart myosin was evaluated on Fraction of actin filaments moving in an in vitro motility assay (p=0.006). Myosin isolated from hypertrophic cardiomyopathy myectomy samples showed a 21% reduction in the fraction of actin filaments moving compared with donor myosin.
Synapse has enriched 10 related papers. Consider them for comparative context: